Can Molecular Imaging Find a Path to Navigate Evolving Breast Cancer Treatments?
Hannah M Linden1, David A Mankoff2,3
1University of Washington Department of Medicine Division of Medical Oncology, Fred Hutchinson Cancer Center Clinical Research Division, Seattle, Washington.
Abstract:
[18F]fluoroestradiol (FES) PET is an FDA-approved imaging biomarker. Like IHC, FES positivity predicts clinical benefit of endocrine therapy. In addition, FES measures the target activity in endocrine agent drug development. A recent study found that whole body tumor heterogeneity of expression predicts clinical benefit, and serial FES monitors estrogen receptor blockade and posttreatment release. See related article by Iqbal et al., p. 2075.


